Global Autoimmune Disorder Drug Delivery Devices Market: Focus on Product Type, Indication, Manufacturing Type, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

"Global Autoimmune Disorders Drug Delivery Devices Market to Reach $10,686.5 Million by 2030."

Market Report Coverage - Autoimmune Disorder Drug Delivery Devices

Market Segmentation

• Indication - Systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis

• Product Type - Pen injectors, auto-injectors, pre-filled syringes, and vials

• Manufacturing Type - In-house manufacturing and outsourced manufacturing

Regional Segmentation

• North America - U.S., Canada
• Europe - Germany, France, Italy, U.K., Spain, and Rest-of-Europe
• Asia-Pacific - China, Japan, India, South Korea, Australia, and Rest-of-APAC
• Latin America - Brazil, Mexico, and Rest-of-the-Latin America
• Rest-of-the-World

Growth Drivers

• Increased Prevalence of Autoimmune Disorders

• Technological Advancements in the Field of Pre-Filled Syringes

• Rising Geriatric Population

• Surge of Biosimilars and Biologics in the Pharmaceutical Market

• Device Connectivity to Ease Competitive Pressure

Market Challenges

• Strict Legal Requirements and Regulations

• Alternative Drug Delivery Technology

Market Opportunities

• Providing Injectable Drug Delivery Devices for Untapped Autoimmune Disorders

• Opportunities of Personalizing Treatments in Autoimmune Diseases

Key Companies Profiled

AbbVie Inc., Amgen Inc., F. Hoffmann- La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Biogen Inc., Merck KGaA, Bayer AG, Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd., Eli Lily and Company, Sanofi S.A., UCB Inc., and Takeda Pharmaceutical Company Limited, among others

Key Questions Answered in this Report:

• What are the various autoimmune disorders drug delivery devices available in the market?

• What are emerging drug delivery devices for the treatment of autoimmune disorders?

• How does the pipeline for global autoimmune disorders drug delivery devices market look like?

• What is the current market size and future potential of these drug delivery devices?

• What are the major market drivers, challenges, and opportunities in the global autoimmune disorders drug delivery devices market?

• What is the patent landscape of this market?

• What will be the impact of COVID-19 on this market?

• What are the guidelines implemented by different government bodies to regulate the approval of autoimmune disorders drug delivery devices?

• What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?

• Who are the leading players holding dominating shares in the global autoimmune disorders drug delivery devices market, currently?

• What are the key strategies incorporated by the players of global autoimmune disorders drug delivery devices market, to sustain the competition and retain their supremacy?

• What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by product type), and how would it evolve in the forecast period?

• What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by indication), and how would it evolve in the forecast period?

• What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by route of administration), and how would it evolve in the forecast period?

• What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by usage type), and how would it evolve in the forecast period?

• What is the current revenue contribution of the global autoimmune disorders drug delivery devices market (by therapeutics), and how would it evolve in the forecast period?

• Which region is expected to contribute to the highest revenue of the global autoimmune disorders drug delivery devices market during the forecast period?

Market Overview

Healthcare experts have found the autoimmune disorders industry to be one of the most rapidly evolving markets. The global market for autoimmune disorder drug delivery devices is predicted to grow at a CAGR of 15.25% over the forecast period of 2020-2030. The market is driven by certain factors, including the increasing global geriatric population, increasing incidence of chronic diseases including autoimmune disorders, and rise in demand for self-injectable systems.

The market is favored by the development of autoimmune disorder drug delivery devices for several clinical areas such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis. The increase in the geriatric population and incurable autoimmune disorders across the globe are expected to translate into a significantly higher demand for autoimmune disorder drug delivery devices.

Furthermore, the companies are investing huge amounts in research and development of autoimmune disorder drug delivery devices. The clinical trial landscape of different autoimmune disorders has been on the rise in recent years, and this will drive the autoimmune disorder drug delivery devices market in the future.

Within the research report, the market is segmented based on indication, product type, manufacturing type, and region. Each of these segments covers the market's snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the adoption of self-injection devices for the treatment of autoimmune disorders has created a buzz among companies to invest in the development of novel autoimmune disorder drug delivery devices. Due to the leading market products and intense market penetration, Amgen Inc. has been a pioneer in this field and has been a significant competitor in this market.

Several other companies, such as Novartis AG, F. Hoffmann- La Roche Ltd., and Bristol Myers Squibb Company, have launched drug delivery devices for autoimmune disorders.

Based on region, North America holds the largest share of the autoimmune disorder drug delivery devices market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at a high CAGR during the forecast period.

Table of Contents

Executive Summary

1 Technology Definition

• 1.1 Inclusion and Exclusion Criteria
  • 1.1.1 Inclusions
  • 1.1.2 Exclusions

2 Research Scope

• 2.1 Key Questions Answered in the Report

3 Research Methodology

• 3.1 Autoimmune Disorder Drug Delivery Devices Market: Research Methodology
• 3.2 Primary Data Sources
• 3.3 Secondary Data Sources
• 3.4 Market Estimation Model
• 3.5 Criteria for Company Profiling

4 Market Overview

• 4.1 Historic Overview and Future Scope of Injectable Drug Delivery Devices
• 4.2 Pre-Filled Syringes Manufacturing and Packaging Challenges
• 4.3 Global Autoimmune Disorder Drug Delivery Devices Market and Growth Potential, 2019-2030
• 4.4 Pricing and Reimbursement Scenario
• 4.5 Impact of Patent Expiry and Entry of Biosimilars on Autoimmune Disorder Drug Delivery Devices Market
• 4.6 Impact of COVID-19 on Autoimmune Disorder Drug Delivery Devices Market

5 Industry Insights

• 5.1 Overview
• 5.2 Legal Requirements and Frameworks Across the Globe
• 5.3 Regulatory Framework and Government Initiatives
• 5.4 Legal Requirements and Frameworks in North America
  • 5.4.1 Food and Drug Administration (FDA)
  • 5.4.2 Health Canada
• 5.5 Legal Requirements and Frameworks in Europe
  • 5.5.1 European Union
• 5.6 Legal Requirements and Frameworks in Asia-Pacific
  • 5.6.1 National Medical Products Administration (NMPA)
  • 5.6.2 Pharmaceutical and Medical Device Agency (PMDA)
  • 5.6.3 Central Drug Standard Control Organization (CDSCO)

6 Patent Landscape

• 6.1 Patent Analysis (by Drug Delivery Devices)
• 6.2 Patent Analysis (by IPC Code)
• 6.3 Patent Analysis (by Country)
• 6.4 Patent Analysis (by Company)

7 Market Dynamics

• 7.1 Overview
• 7.2 Impact Analysis
• 7.3 Drivers
  • 7.3.1 Increased Prevalence of Autoimmune Disorders
  • 7.3.2 Technological Advancements in the Field of Pre-Filled Syringes
  • 7.3.3 Rising Geriatric Population
  • 7.3.4 Surge of Biosimilars and Biologics in the Pharmaceutical Market
  • 7.3.5 Device Connectivity to Ease Competitive Pressure
• 7.4 Restraints
  • 7.4.1 Strict Legal Requirements and Regulations
  • 7.4.2 Alternative Drug Delivery Technology
• 7.5 Opportunities
  • 7.5.1 Providing Injectable Drug Delivery Devices for Untapped Autoimmune Disorders
  • 7.5.2 Opportunities for Personalizing Treatments in Autoimmune Diseases

8 Global Autoimmune Disorder Drug Delivery Devices Market, (by Indication), $Million, 2019-2030

• 8.1 Rheumatoid Arthritis
• 8.2 Psoriasis
• 8.3 Multiple Sclerosis
• 8.4 Inflammatory Bowel Diseases
• 8.5 Systemic Lupus Erythematosus

9 Global Autoimmune Disorder Drug Delivery Devices Market, (by Product), $Million, 2019-2030

• 9.1 Introduction
• 9.2 Pen Injectors
• 9.3 Auto-Injectors
• 9.4 Pre-filled Syringes
• 9.5 Vials

10 Global Autoimmune Disorder Drug Delivery Devices Market, (by Manufacturing Type), $Million, 2019-2030

• 10.1 In-House Manufacturing
• 10.2 Outsourced Manufacturing

11 Global Autoimmune Disorder Drug Delivery Devices Market, (by Region), $Million, 2019-2030

• 11.1 Overview
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 U.K.
  • 11.3.3 France
  • 11.3.4 Italy
  • 11.3.5 Spain
  • 11.3.6 Rest-of-Europe
• 11.4 Asia-Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 South Korea
  • 11.4.5 Australia
  • 11.4.6 Rest-of-APAC
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest-of-Latin America
• 11.6 Rest-of-the-World

12 Competitive Landscape

• 12.1 Key Developments and Strategies
  • 12.1.1 Regulatory and Legal Developments
  • 12.1.2 Partnerships, Alliances, and Business Expansions
  • 12.1.3 Mergers and Acquisitions
• 12.2 Market Share Analysis

13 Company Profiles

• 13.1 Overview
• 13.2 Amgen Inc.
  • 13.2.1 Company Overview
  • 13.2.2 Role of Amgen Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.2.3 Financials
  • 13.2.4 Key Insights about Financial Health of the Company
  • 13.2.5 SWOT Analysis
• 13.3 AbbVie Inc.
  • 13.3.1 Company Overview
  • 13.3.2 Role of AbbVie Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.3.3 Financials
  • 13.3.4 Key Insights about Financial Health of the Company
  • 13.3.5 SWOT Analysis
• 13.4 Bayer AG
  • 13.4.1 Company Overview
  • 13.4.2 Role of Bayer AG in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.4.3 Financials
  • 13.4.4 Key Insight about Financial Health of the Company
  • 13.4.5 SWOT Analysis
• 13.5 Biogen Inc.
  • 13.5.1 Company Overview
  • 13.5.2 Role of Biogen Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.5.3 Financials
  • 13.5.4 Key Insights about Financial Health of the Company
  • 13.5.5 SWOT Analysis
• 13.6 Bristol-Myers Squibb Company
  • 13.6.1 Company Overview
  • 13.6.2 Role of Bristol Myers Squibb Company in the Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.6.3 Financials
  • 13.6.4 Key Insights About Financial Health of the Company
  • 13.6.5 SWOT Analysis
• 13.7 Eli Lilly & Company
  • 13.7.1 Company Overview
  • 13.7.2 Role of Eli Lilly & Company in Global Autoimmune Disorder Drug Delivery Device Market
  • 13.7.3 Financials
  • 13.7.4 Key Insights About Financial Health of the Company
  • 13.7.5 SWOT Analysis
• 13.8 F. Hoffmann-La Roche Ltd
  • 13.8.1 Company Overview
  • 13.8.2 Role of F. Hoffmann-La Roche Ltd. in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.8.3 Financials
  • 13.8.4 Key Insights About Financial Health of the Company
  • 13.8.5 SWOT Analysis
• 13.9 GlaxoSmithKline plc
  • 13.9.1 Company Overview
  • 13.9.2 Role of GlaxoSmithKline plc in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.9.3 Financials
  • 13.9.4 Key Insights About Financial Health of the Company
  • 13.9.5 SWOT Analysis
• 13.1 Johnson & Johnson Services, Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Role of Johnson & Johnson Services, Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.10.3 Financials
  • 13.10.4 Key Insights About Financial Health of the Company
  • 13.10.5 SWOT Analysis
• 13.11 Merck KGaA
  • 13.11.1 Company Overview
  • 13.11.2 Role of Merck KGaA in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.11.3 Financials
  • 13.11.4 Key Insights About Financial Health of the Company
  • 13.11.5 SWOT Analysis
• 13.12 Novartis AG
  • 13.12.1 Company overview
  • 13.12.2 Role of Novartis AG in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.12.3 Financials
  • 13.12.4 Key Insights About Financial Health of the Company
  • 13.12.5 SWOT Analysis
• 13.13 Sanofi S.A.
  • 13.13.1 Company Overview
  • 13.13.2 Role of Sanofi S.A. in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.13.3 Financials
  • 13.13.4 Key Insights About Financial Health of the Company
  • 13.13.5 SWOT Analysis
• 13.14 Teva Pharmaceutical Industries Ltd.
  • 13.14.1 Company Overview
  • 13.14.2 Role of Teva Pharmaceutical Industries Ltd. in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.14.3 Financials
  • 13.14.4 Key Insight About Financial Health of the Company
  • 13.14.5 SWOT Analysis
• 13.15 UCB Pharma SA.
  • 13.15.1 Company Overview
  • 13.15.2 Role of UCB Pharma SA in Global Autoimmune Disorder Drug Delivery Devices Market
  • 13.15.3 Financials
  • 13.15.4 Key Insight About Financial Health of the Company
  • 13.15.5 SWOT Analysis

List of Figures

• Figure 1: Global Prevalence of Rheumatoid Arthritis (1990-2017)
• Figure 2: Global Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 3: Impact Analysis
• Figure 4: Share of Key Developments and Strategies, (September 2017-September 2020)
• Figure 5: Global Autoimmune Disorder Drug Delivery Devices Market (by Product), ($Million), 2019 and 2030
• Figure 6: Global Autoimmune Disorder Drug Delivery Devices Market (by Indication), ($Million), 2019 and 2030
• Figure 7: Global Autoimmune Disorder Drug Delivery Devices Market (by Manufacturing Type), ($Million), 2019 and 2030
• Figure 8: Global Autoimmune Disorder Drug Delivery Devices Market (by Region), ($Million), 2019-2030
• Figure 2.1: Global Autoimmune Disorders Drug Delivery Devices Market Segmentation
• Figure 3.1: Global Autoimmune Disorder Drug Delivery Devices Market Methodology
• Figure 3.2: Primary Research Methodology
• Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
• Figure 4.1: Key Milestones in History of Syringes
• Figure 4.2: Advancements in Injectable Drug Delivery Technology
• Figure 4.3: Global Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 5.1: Global Autoimmune Disorder Drug Delivery Devices Market: Regulatory Landscape
• Figure 5.2: FDA 510(k) Approval Timeline
• Figure 5.3: Health Canada Class II-Medical Device Approval Process
• Figure 5.4: European Commission Class IIa-Medical Device Approval Process
• Figure 5.5: National Medical Products Administration Class III-Medical Device Approval Process
• Figure 5.6: Pharmaceutical and Medical Devices Agency (PMDA) Class II-Medical Device Approval Process
• Figure 5.7: Central Drug Standard Control Organization (CDSCO) Class B-Medical Device Approval Process
• Figure 6.1: Number of Patents Filed, Autoimmune Disorders Drug Delivery Devices, January 2017-December 2019
• Figure 6.2: Patent Analysis (by IPC Code)
• Figure 6.3: Patent Analysis (by Country)
• Figure 6.4: Patent Analysis (by Company)
• Figure 7.1: Impact Analysis
• Figure 7.2: Global Prevalence of Rheumatoid Arthritis (1990-2017)
• Figure 7.3: Technological Advancements in Pre-Filled Syringes Over Time
• Figure 7.4: Global Geriatric Population (by Age)
• Figure 7.5: Analysis of Origin of Drugs to Treat Autoimmune Disorders
• Figure 7.6: Opportunity Areas for Injectable Drug Delivery Devices
• Figure 8.1: Global Autoimmune Disorder Drug Delivery Devices Market, by Indication
• Figure 8.2: Global Autoimmune Disorder Drug Delivery Devices Market (by Indication), ($Million), 2019 and 2030
• Figure 8.3: Global Autoimmune Disorder Drug Delivery Devices Market (by Rheumatoid Arthritis), ($Million), 2019-2030
• Figure 8.4: Rheumatoid Arthritis Drug Delivery Devices Market (By Therapeutics), ($Million), 2017-2019
• Figure 8.5: Global Autoimmune Disorder Drug Delivery Devices Market (by Psoriasis), ($Million), 2019-2030
• Figure 8.6: Psoriasis Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
• Figure 8.7: Global Autoimmune Disorder Drug Delivery Devices Market (by Multiple Sclerosis), ($Million), 2019-2030
• Figure 8.8: Multiple Sclerosis Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
• Figure 8.9: Global Autoimmune Disorder Drug Delivery Devices Market (by Inflammatory Bowel Diseases), ($Million), 2019-2030
• Figure 8.10: Inflammatory Bowel Diseases Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
• Figure 8.11: Global Autoimmune Disorder Drug Delivery Devices Market (Systemic Lupus Erythematosus), ($Million), 2019-2030
• Figure 8.12: Systemic Lupus Erythematosus Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
• Figure 9.1: Revenue Contribution of Different Products, 2019 and 2030
• Figure 9.2: Global Autoimmune Disorder Drug Delivery Devices Market (Pen Injectors), ($Million), 2019-2030
• Figure 9.3: Pen Injector based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
• Figure 9.4: Global Autoimmune Disorder Drug Delivery Devices Market (Auto-injectors), ($Million), 2019-2030
• Figure 9.5: Auto-Injector based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
• Figure 9.6: Global Autoimmune Disorder Drug Delivery Devices Market (Pre-filled Syringes), ($Million), 2019-2030
• Figure 9.7: Pre-filled Syringes based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
• Figure 9.8: Global Autoimmune Disorder Drug Delivery Devices Market (Vials), ($Million), 2019-2030
• Figure 9.9: Vials based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
• Figure 10.1: Global Autoimmune Disorder Drug Delivery Devices Market (by Manufacturing Type), ($Million), 2019 and 2030
• Figure 10.2: Global Autoimmune Disorder Drug Delivery Devices Market (by In-house Manufacturing), ($Million), 2019-2030
• Figure 10.3: Global Autoimmune Disorder Drug Delivery Devices Market (by Outsourced Manufacturing), ($Million), 2019-2030
• Figure 11.1: Global Autoimmune Disorder Drug Delivery Devices Market (by Region)
• Figure 11.2: Global Autoimmune Disorder Drug Delivery Devices Market (by Region), ($Million), 2019-2030
• Figure 11.3: North America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.4: North America: Market Dynamics
• Figure 11.5: Revenue Contributions of Different Countries in North America, ($Million), 2019 and 2030
• Figure 11.6: U.S. Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.7: Canada Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.8: Europe Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.9: Europe: Market Dynamics
• Figure 11.10: Revenue Contributions Different Countries in Europe, ($Million), 2019 and 2030
• Figure 11.11: Germany Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.12: U.K. Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.13: France Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.14: Italy Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.15: Spain Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.16: Rest-of-Europe Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.17: Asia-Pacific Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.18: APAC: Market Dynamics
• Figure 11.19: Revenue Contributions Different Countries in Asia-Pacific, ($Million), 2019 and 2030
• Figure 11.20: China Autoimmune Disorder Drug Delivery Devices market, ($Million), 2019-2030
• Figure 11.21: Japan Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.22: India Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.23: South Korea Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.24: Australia Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.25: RoAPAC Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.26: Latin America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.27: Latin America: Market Dynamics
• Figure 11.28: Revenue Contributions of Different Countries in Latin America, ($Million), 2019 and 2030
• Figure 11.29: Brazil Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.30: Mexico Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.31: Rest-of-Latin America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 11.32: RoW Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
• Figure 12.1: Share of Key Developments and Strategies, September 2017-September 2020
• Figure 12.2: Regulatory and Legal Developments Share (by Company), September 2017- September 2020
• Figure 12.3: Partnerships, Alliances, and Business Expansions (by Company), September 2017-September 2020
• Figure 12.4: Mergers and Acquisitions Share (by Company), September 2017-September 2020
• Figure 12.5: Market Share Analysis (by Companies), 2018 and 2019
• Figure 13.1: Total Number of Companies Profiled
• Figure 13.2: Amgen Inc.: Overall Product Portfolio
• Figure 13.3: Amgen Inc.: Overall Financials, 2017-2019
• Figure 13.4: Amgen Inc.: Revenue (by Region), 2017-2019
• Figure 13.5: Amgen Inc.: R&D Expenditure, 2017-2019
• Figure 13.6: Amgen Inc.: SWOT Analysis
• Figure 13.7: AbbVie Inc.: Overall Product Portfolio
• Figure 13.8: AbbVie Inc.: Overall Financials, 2017-2019
• Figure 13.9: AbbVie Inc.: Revenue (by Region), 2017-2019
• Figure 13.10: AbbVie Inc.: R&D Expenditure, 2017-2019
• Figure 13.11: AbbVie Inc.: SWOT Analysis
• Figure 13.12: Bayer AG: Overall Product Portfolio
• Figure 13.13: Bayer AG: Overall Financials, 2017-2019
• Figure 13.14: Bayer AG: Revenue (by Segment), 2018-2019
• Figure 13.15: Bayer AG: Revenue (by Region), 2017-2019
• Figure 13.16: Bayer AG: R&D Expenditure, 2017-2019
• Figure 13.17: Bayer AG: SWOT Analysis
• Figure 13.18: Biogen Inc.: Overall Service Portfolio
• Figure 13.19: Biogen Inc.: Overall Financials, 2017-2019
• Figure 13.20: Biogen Inc.: Sales (by Product), 2017-2019
• Figure 13.21: Biogen Inc.: Sales (by Region), 2017-2019
• Figure 13.22: Biogen Inc.: R&D Expenditure, 2017-2019
• Figure 13.23: Biogen Inc.: SWOT Analysis
• Figure 13.24: Bristol Myers Squibb Company: Overall Product Portfolio
• Figure 13.25: Bristol Myers Squibb Company: Overall Financials, 2017-2019
• Figure 13.26: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
• Figure 13.27: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
• Figure 13.28: Bristol Myers Squibb Company: SWOT Analysis
• Figure 13.29: Eli Lilly & Company: Product Portfolio
• Figure 13.30: Eli Lilly & Company: Pipeline Product Portfolio
• Figure 13.31: Eli Lilly & Company: Overall Financials, 2017-2019
• Figure 13.32: Eli Lilly & Company: Revenue (by Region), 2017-2019
• Figure 13.33: Key Insights About Financial Health of the Company
• Figure 13.34: Eli Lilly & Company: SWOT Analysis
• Figure 13.35: F. Hoffmann-La Roche Ltd: Product Portfolio
• Figure 13.36: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
• Figure 13.37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
• Figure 13.38: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
• Figure 13.39: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
• Figure 13.40: F. Hoffmann-La Roche Ltd: SWOT Analysis
• Figure 13.41: GlaxoSmithKline plc: Pipeline Product Portfolio
• Figure 13.42: GlaxoSmithKline plc: Overall Financials, 2017-2019
• Figure 13.43: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
• Figure 13.44: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
• Figure 13.45: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
• Figure 13.46: GlaxoSmithKline plc: SWOT Analysis
• Figure 13.47: Johnson & Jonson Services, Inc.: Product Portfolio
• Figure 13.48: Johnson & Jonson Services, Inc.: Pipeline Products Portfolio
• Figure 13.49: Johnson & Johnson Services, Inc. Company: Overall Financials, 2017-2019
• Figure 13.50: Johnson & Johnson Services, Inc. Company: R&D Expenditure, 2017-2019
• Figure 13.51: Johnson & Johnson Services, Inc.: SWOT Analysis
• Figure 13.52: Merck KGaA: Product Portfolio
• Figure 13.53: Merck KGaA: Overall Financials, 2017-2019
• Figure 13.54: Merck KGaA: Revenue (by Segment), 2017-2019
• Figure 13.55: Merck KGaA: Revenue (by Region), 2017-2019
• Figure 13.56: Merck KGaA: R&D Expenditure, 2017-2019
• Figure 13.57: Merck KGaA: SWOT Analysis
• Figure 13.58: Novartis AG: Products Portfolio
• Figure 13.59: Novartis AG: Pipeline Products Portfolio
• Figure 13.60: Novartis AG: Overall Financials, 2017-2019
• Figure 13.61: Novartis AG Net Revenue (by Business Segment), 2017-2019
• Figure 13.62: Novartis AG: Net Revenue (by Region), 2017-2019
• Figure 13.63: Novartis AG: R&D Expense, 2017-2019
• Figure 13.64: Novartis AG: SWOT Analysis
• Figure 13.65: Sanofi S.A.: Overall Product Portfolio
• Figure 13.66: Sanofi S.A.: Overall Financials, 2017-2019
• Figure 13.67: Sanofi S.A.: Revenue (by Segment), 2017-2019
• Figure 13.68: Sanofi S.A.: Revenue (by Region), 2017-2019
• Figure 13.69: Sanofi S.A.: R&D Expenditure, 2017-2019
• Figure 13.70: Sanofi S.A.: SWOT Analysis
• Figure 13.71: Teva Pharmaceutical Industries Ltd.: Overall Product Portfolio
• Figure 13.72: Teva Pharmaceutical Industries Ltd.: Overall Financials, 2017-2019
• Figure 13.73: Teva Pharmaceutical Industries Ltd.: Net Revenue (by Business Segment), 2017-2019
• Figure 13.74: Teva Pharmaceutical Industries Ltd.: Research and Development Expense, 2017-2019
• Figure 13.75: Teva Pharmaceutical Industries Ltd.: SWOT Analysis
• Figure 13.76: UCB Pharma SA: Overall Product Portfolio
• Figure 13.77: UCB Pharma SA: Overall Product Portfolio
• Figure 13.78: UCB Pharma SA: Overall Financials, 2017-2019
• Figure 13.79: UCB Pharma SA: Revenue (by Product), 2017-2019
• Figure 13.80: UCB Pharma SA: Revenue (by Region), 2017-2019
• Figure 13.81: UCB Pharma SA: R&D Expenditure, 2017-2019
• Figure 13.82: UCB Pharma SA: SWOT Analysis

List of Tables

• Table 1: Leading Players in Global Autoimmune Disorder Drug Delivery Devices Market
• Table 4.1: Patent Expiry of Autoimmune Disorder Therapeutics
• Table 5.1: Legal Requirements and Frameworks Across the Globe
• Table 7.1: Deaths Due to Multiple Sclerosis in Key Countries, 2015-2017
• Table 7.2: Filing Requirements for Pre-filled Syringes:
• Table 7.3: Differentiation of an Injectable Therapeutic Throughout its Life Cycle:
• Table 7.4: Alternative Drug Delivery Technologies:
• Table 8.1: Global Autoimmune Disorder Therapeutics Sales, 2017-2019